reglab/statecodes huggingface dataset:
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter B - Prohibitions, Sanctions and Exceptions › Section XLV-6511 - Reinstatement of Registration

Current through Register Vol. 50, No. 6, June 20, 2024
A. The
					 board may reinstate any registration which has been suspended, revoked,
					 canceled, conditioned, or restricted by the board; provided, however, that no
					 registration which has been revoked or canceled shall be reinstated by the
					 board within five years of the effective date of such revocation or
					 cancellation.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter C - Registration › Section XLV-6513 - Eligibility for Registration as a Dispensing Physician

Current through Register Vol. 50, No. 6, June 20, 2024
A. To be eligible for registration as a
					 dispensing physician for all medication, including but not limited to
					 controlled substances and drugs of concern, a physician shall, as of the date
					 of the application:
1. possess a current,
					 unrestricted license to practice medicine duly issued by the board;
2. have been in the active practice of
					 medicine for not less than three years following the date on which the
					 physician was awarded a doctor of medicine or doctor of osteopathy
					 degree;
3. not currently be
					 enrolled in a medical residency or other post graduate medical training
					 program; and
. possess a current,
						unrestricted license to prescribe, dispense, and administer controlled
						substances duly issued by the Office of Narcotics and Dangerous Drugs,
						Department of Health and Human Resources, state of Louisiana, and be currently
						registered to prescribe, dispense, and administer controlled substances,
						without restriction, with the Drug Enforcement Administration, United States
						Department of Justice.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter C - Registration › Section XLV-6515 - Registration Procedure

Current through Register Vol. 50, No. 6, June 20, 2024
A.
					 Application for registration as a dispensing physician shall be made upon forms
					 supplied by the board.
B.
					 Application forms and instructions pertaining thereto may be obtained upon
					 written request directed to the office of the board.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter C - Registration › Section XLV-6517 - Original Application

Current through Register Vol. 50, No. 6, June 20, 2024
A. An
					 application for registration as a dispensing physician under this Chapter shall
					 include:
1. the applicant's full name, home
					 address, and the municipal and post office addresses of each office or other
					 location at which the applicant practices medicine in the state of
					 Louisiana;
2. the name, municipal
					 and post office address of the medical firm or firms, if any, with which the
					 applicant is associated, and the full names of all physician partners or
					 employees of such firm or firms;
3.
					 the applicant's Louisiana controlled dangerous substance license number and the
					 applicant's United States Drug Enforcement Agency (DEA) controlled substance
					 registration number;
4. the
					 municipal and post office addresses and telephone number of each location at
					 which the applicant dispenses or proposes to dispense medications;
5. a designation of the schedules, classes,
					 types, or specific medications which the applicant dispenses or proposes to
					 dispense;
6. certification by
					 affidavit or other proof, documented in a form satisfactory to the board as
					 specified by the secretary, that the applicant possess the qualifications for
					 registration set forth by this Chapter; and
7. such other information and documentation
					 as the board may require to evidence qualification for registration as a
					 dispensing physician.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter C - Registration › Section XLV-6519 - Effect of Application

Current through Register Vol. 50, No. 6, June 20, 2024
A. The
					 submission of an application for registration as a dispensing physician shall
					 have the same effect as the submission of an application for medical licensure,
					 as provided in Board
					 Rule
					 365 (to be codified at §1145 of
					 these rules).
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter C - Registration › Section XLV-6521 - Certification of Registration

Current through Register Vol. 50, No. 6, June 20, 2024
A. If
					 the qualifications, requirements, and procedures prescribed or incorporated by
					 §6513 are met to the satisfaction of the
					 board, the board shall issue to the applicant certification of registration as
					 a dispensing physician bearing the Dispensing Physician Registration Number
					 (DPRN). The original of such certificate, or a duplicate thereof certified by
					 the board, shall be maintained at each location at which the registrant
					 dispenses medications.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter C - Registration › Section XLV-6523 - Expiration of Registration

Current through Register Vol. 50, No. 6, June 20, 2024
A.
					 Registration with the board as a dispensing physician under this Chapter shall
					 expire, and thereby become null, void, and to no effect, on the last day of the
					 year for which such registration was made and certified.
B. Notwithstanding the provisions of §6523 A, every registration issued by the board under this Chapter, to be effective
					 on or after January 1, 1999, and each year thereafter, shall expire, and
					 thereby become null, void and to no effect the following year on the first day
					 of the month in which the registrant was born.
C. The timely submission of an application
					 for renewal of registration as a dispensing physician, as provided by
					 §6525 of this Chapter, shall operate to
					 continue the expiring registration in effect pending certification of renewal
					 registration or other final action by the board on such application for
					 renewal.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter C - Registration › Section XLV-6525 - Renewal of Registration

Current through Register Vol. 50, No. 6, June 20, 2024
A.
					 Registration as a dispensing physician under this Chapter shall be renewed
					 annually on or before its date of expiration by submitting to the board an
					 application for renewal, upon forms supplied by the board, together with a
					 registration renewal fee of $50.
B.
					 Notwithstanding the provisions of §6525 A, every registration issued by the
					 board under this Chapter to be effective on or after January 1, 1999, shall be
					 renewed in the year 2000, and each year thereafter, on or before the first day
					 of the month in which the registrant was born. Renewal fees shall be prorated
					 if the registration is to be effective for more than one year.
C. An application for registration renewal
					 form shall be mailed by the board to each registrant at least 30 days prior to
					 the expiration of the registration each year. Such form shall be mailed to the
					 most recent address of each registrant as reflected in the official records of
					 the board.
D. Registration as a
					 dispensing physician which has expired by virtue of nonrenewal shall not be
					 reinstated by the board except upon the applicant's satisfaction of the
					 qualifications, requirements and procedures prescribed by this Chapter for
					 original application for registration.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6527 - Purchases, Acquisitions

Current through Register Vol. 50, No. 6, June 20, 2024
A. Each
					 registrant shall maintain current, accurate, complete, and readily retrievable
					 records of all transactions by which the registrant orders, purchases,
					 acquires, receives, or otherwise comes into possession or custody of
					 medications, other than bona fide medication samples, for dispensation or
					 administration to patients.
B. The
					 records required to be maintained by this Section shall include:
1. a record of each order, purchase, or other
					 acquisition made or placed by the registrant for medications, including:
a. a photocopy, counterfoil carbon copy, or
					 other duplicate of each original order or purchase form;
b. the full name and address of the person,
					 firm, or entity from whom the medications were ordered, purchased, or otherwise
					 acquired;
c. the date of the order,
					 purchase, or other acquisition; and
d. the generic chemical or trade name,
					 quantity, or amount, and dosage strength of each medication ordered, purchased,
					 or otherwise acquired; and
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6529 - Medication Inventories

Current through Register Vol. 50, No. 6, June 20, 2024
A. Each
					 registrant shall maintain current, accurate, and complete records, in writing
					 or electronically recorded so as to be readily convertible into writing, of the
					 generic chemical or trade name, and exact quantity or amount and location of
					 all medications in the registrant's possession or custody, which records shall,
					 not less frequently than monthly, be updated to reflect and account for all
					 purchases, acquisitions, dispensations, transfers, losses of, or other
					 transactions involving the medications in the registrant's
					 possession.
B. Not less frequently
					 than quarterly during each calendar year, each registrant shall conduct or
					 cause to be conducted a physical inventory of all medications in the possession
					 or custody of the registrant for each location at which the registrant
					 maintains or stores medications and shall conduct reasonable inquiry to
					 determine and to record the nature and cause of any discrepancy between such
					 physical inventory and the kind and amount of medications evidenced by the
					 records required under the preceding paragraph of this Section. A record of
					 each such quarterly physical inventory and reconciliation shall be made and
					 retained by the registrant.
C. A
					 registrant shall conduct or cause to be conducted a physical inventory of all
					 medications in the possession or custody of the registrant for each location at
					 which the registrant maintains or stores medication and shall conduct
					 reasonable inquiry to determine and to record the nature and cause of any
					 discrepancy between such physical inventory and the kind and amount of
					 medications evidenced by the records required under §6529 A, within 20 days of
					 the date on which:
1. a registrant's license
					 to practice medicine or registration as a dispensing physician is suspended,
					 revoked, canceled, or expires by virtue of nonrenewal;
2. the registrant terminates, concludes,
					 sells, assigns, or retires from his practice of medicine; or
3. medications in the registrant's possession
					 are seized under executory process, sequestration, attachment, bankruptcy, or
					 by authority of any federal, state, or local regulatory or law enforcement
					 agency.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6531 - Dispensation Records

Current through Register Vol. 50, No. 6, June 20, 2024
A. Each
					 registrant shall, concurrently with the dispensation or administration of any
					 medication, record the generic chemical or trade name of any medication
					 dispensed or administered, other than bona fide medication samples, the
					 quantity or amount and dosage strength of such medication, the date on which
					 such medication was dispensed or administered, and the full name and address of
					 the patient to whom or for whom such medication was dispensed or
					 administered.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6533 - Other Transaction Records

Current through Register Vol. 50, No. 6, June 20, 2024
A.
					 A registrant shall, concurrently with the transfer or delivery of any
					 medication in his possession to any other location or with the sale, delivery,
					 return, or other transfer of any medication to any other registrant, physician,
					 person, firm, or entity, other than by dispensation to a patient, record the
					 generic chemical or trade name of any medication so sold, delivered, returned,
					 or transferred, the quantity or amount and dosage strength of such medication,
					 the date on which such medication was sold, delivered, returned, or
					 transferred, and the name, address, and DEA registration number of the person,
					 firm, or entity to whom such medication was sold, delivered, returned, or
					 otherwise transferred.
B. Each
					 registrant shall, with respect to any medication intentionally disposed of or
					 destroyed, concurrently with such destruction or disposal, record the generic
					 chemical or trade name, quantity or amount, and dosage strength of such
					 medication, the date of its destruction or disposal and the reasons for or
					 circumstances surrounding its destruction or disposal.
C. A registrant shall record the generic
					 chemical and trade name, quantity and amount, and dosage strength of any
					 medication lost, stolen, accidentally destroyed, or otherwise unaccounted for,
					 together with the date of and reasons for or circumstances surrounding such
					 loss, theft, accidental destruction, or other such disposition.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6535 - Separate Maintenance Records for Schedule II Substances

Current through Register Vol. 50, No. 6, June 20, 2024
A. All records
					 required to be maintained by this Subchapter relating to medications designated
					 as Schedule II controlled substances by state or federal law or regulations
					 shall be maintained separately from all such records relating to other
					 medications.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6537 - Computerized Records

Current through Register Vol. 50, No. 6, June 20, 2024
A. Any record
					 required by this Subchapter, other than original or duplicate order and
					 receiving invoice forms and prescriptions, may be recorded and stored on a
					 computerized, electronic data processing system provided that such system is
					 designed so as to ensure that the records and information so recorded are
					 accurate, complete, and readily retrievable and convertible to hard copy
					 printout and provided further that such system satisfies standards of security
					 prescribed by §6549
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6539 - Retention of Records

Current through Register Vol. 50, No. 6, June 20, 2024
A. All records
					 and documents required by this Subchapter shall be securely maintained, in
					 accordance with the standards of security prescribed by §6547, for a period of
					 not less than five years from the date on which the subject data is first
					 recorded.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter D - Recordkeeping › Section XLV-6541 - Board Access to Records

Current through Register Vol. 50, No. 6, June 20, 2024
A. The
					 records required by this Subchapter shall be available for examination,
					 inspection, copying, and verification of accuracy, currency, and completeness
					 by the board or its designated employee or agent at any reasonable time, but
					 without the necessity of prior notice by the board. The failure or refusal of a
					 registrant to make such records available to the board pursuant to this Section
					 shall constitute a violation of these rules subjecting the registrant to
					 suspension or revocation of medical licensure or registration as a dispensing
					 physician.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter E - Labeling and Packaging › Section XLV-6543 - Labeling

Current through Register Vol. 50, No. 6, June 20, 2024
A. No registrant
					 shall dispense any medication, other than a bona fide medication sample, unless
					 the bottle, package, or other container for such medication bear a
					 securely-affixed indelible, legible, typewritten, or printed label including:
1. the name and address of the
					 registrant;
2. the name of the
					 patient to whom or for whom dispensed;
3. the generic chemical or trade name,
					 quantity or amount, dosage form, and strength of the medication
					 dispensed;
4. the date of
					 dispensation; and
5. appropriate
					 directions for self-administration, ingestion, insertion, application, or
					 injection by the patient.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter E - Labeling and Packaging › Section XLV-6545 - Packaging for Dispensation

Current through Register Vol. 50, No. 6, June 20, 2024
A.
					 Medications shall be dispensed in such bottles, containers, or other packages
					 as may be reasonably necessary or appropriate to safeguard the dispensed
					 medication against contamination, adulteration or deterioration, or spillage or
					 other inadvertent loss.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter F - Security › Section XLV-6547 - Storage of Medications

Current through Register Vol. 50, No. 6, June 20, 2024
A. All
					 medications in the possession of a registrant shall be physically stored and
					 maintained in such location and in such manner as to reasonably secure all such
					 medications against contamination, adulteration, deterioration, loss,
					 accidental destruction, theft, and access or use by unauthorized
					 persons.
B. Medications which are
					 Schedule II controlled substances shall, in addition, be stored and maintained
					 in a metal cabinet, box, safe, vault, or other container of suitable strength
					 and in such location as to safeguard such medication against loss or
					 destruction by fire, flood, or other accidental causes. Such repository shall
					 further be equipped with a secure lock so as to prevent theft of or
					 unauthorized access to or use of such medications.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter F - Security › Section XLV-6549 - Security for Records

Current through Register Vol. 50, No. 6, June 20, 2024
A. The records
					 and documents required under Subchapter D of these rules shall be kept, stored,
					 and maintained in such location and manner as to reasonably secure such records
					 and documents against lost, destruction, theft, or access by unauthorized
					 persons.
B. All records and
					 documents required under Subchapter D of these rules relating to Schedule II
					 controlled substances shall be kept, stored, and maintained in such manner and
					 in such location as is specified by
					 §6547 for the storage of Schedule II
					 controlled substances.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter F - Security › Section XLV-6551 - Maintenance of Computerized Records

Current through Register Vol. 50, No. 6, June 20, 2024
A. Records, information, and data recorded
					 and stored on computerized, electronic data processing equipment, as permitted
					 by this Chapter, shall be periodically, and not less frequently than monthly,
					 duplicated on electronic/magnetic media or converted to hard copy printout, and
					 such duplicate media or printout shall be stored and maintained separately from
					 the central or original data memory in accordance with the standards of
					 security prescribed by §6549
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter G - Reporting › Section XLV-6553 - Theft or Unexplained Loss of Controlled Substances

Current through Register Vol. 50, No. 6, June 20, 2024
A. Any theft or unexplained loss of
					 controlled substances in the possession of a registrant shall be reported by
					 the registrant to the board, in writing, within 10 days of the date of the
					 registrant's discovery of such theft or loss, but in no event later than 10
					 days following the completion of the quarterly physical inventory next
					 following such theft or loss. Such written report shall state the date or
					 estimated date of such theft or loss, the generic chemical or trade name,
					 amount or quantity, and dosage form and strength of any medications stolen or
					 lost and a detailed description of the circumstances surrounding the theft or
					 loss.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter G - Reporting › Section XLV-6555 - Termination of Practice or Dispensation

Current through Register Vol. 50, No. 6, June 20, 2024
A. Not later than 10 days following the date
					 on which a registrant terminates, concludes, sells, assigns, or retires from
					 his practice of medicine or ceases dispensation and administration of
					 medications, the registrant shall report the same to the board in writing. Upon
					 completion of the physical inventory and reconciliation required in such event
					 by §6529 hereof, the
					 registrant shall deliver to the board a copy of such physical inventory record
					 and reconciliation, together with his certificate of registration as a
					 dispensing physician.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter G - Reporting › Section XLV-6557 - Diversion of Medications

Current through Register Vol. 50, No. 6, June 20, 2024
A. A
					 registrant shall immediately report to the board, in writing, any known or
					 reasonably suspected instance of diversion of medications to unauthorized use
					 or possession by any patient or any other person.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter G - Reporting › Section XLV-6559 - Other Reporting Requirements Unaffected

Current through Register Vol. 50, No. 6, June 20, 2024
A. The reporting requirements imposed by this
					 Subchapter do not relieve a registrant of any other reporting requirements
					 imposed by existing state or federal laws or regulations.
B. Any report required by this Subchapter
					 which is also required to be made in substantially the same form and content to
					 any other regulatory or law enforcement agency by state or federal law or
					 regulations may be made by submitting to the board, within the time prescribed
					 by this Subchapter, a photocopy or other duplicate of the reporting form
					 submitted or to be submitted to any such state or federal agency.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 65 - Dispensation of Medications › Subchapter H - Registrant Responsibilities › Section XLV-6561 - Personal Responsibility

Current through Register Vol. 50, No. 6, June 20, 2024
A. A
					 registrant is personally responsible for knowledge of and compliance with the
					 provisions, requirements, and procedures set forth in this Chapter and with
					 knowledge of and compliance with all other federal, state, and local laws and
					 regulations applicable to the purchase, acquisition, possession, storage,
					 maintenance, and dispensation of and recordkeeping and reporting for
					 medication.
AUTHORITY NOTE:
						Promulgated in accordance with R.S. 37:1261-1292 and
						37:1204.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 67 - Preventing Transmission of Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) during Exposure-Prone Invasive Procedures › Section XLV-6701 - Scope of Chapter

Current through Register Vol. 50, No. 6, June 20, 2024
A. As
				  authorized and mandated by
				  R.S.
				  37:1747, the rules of this Chapter prescribe
				  practice and reporting requirements for physicians, podiatrists, physician's
				  assistants, respiratory therapists, and other board-licensed or certified
				  practitioners to protect the public from the risk of the transmission of
				  Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV).
AUTHORITY NOTE:
					 Promulgated in accordance with R.S. 37:1746-1747 and
					 37:1270(B)(6).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 67 - Preventing Transmission of Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) during Exposure-Prone Invasive Procedures › Section XLV-6707 - Prohibitions and Restrictions

Current through Register Vol. 50, No. 6, June 20, 2024
A.
				  Except as may be permitted pursuant to
				  §6709 of this Chapter, a practitioner
				  who is HBsAg seropositive or HIV seropositive, or who otherwise knows or should
				  know that he or she carries and is capable of transmitting HBV or HIV, shall
				  not thereafter perform or participate directly in an exposure-prone
				  procedure.
AUTHORITY NOTE:
					 Promulgated in accordance with R.S. 37:1746-1747 and
					 37:1270(B)(6).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 67 - Preventing Transmission of Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) during Exposure-Prone Invasive Procedures › Section XLV-6709 - Exception; Informed Consent of Patient

Current through Register Vol. 50, No. 6, June 20, 2024
A. Conditions. Notwithstanding the
				  prohibition of
				  §6707 of this Chapter, an HBsAg or HIV
				  seropositive practitioner may nonetheless perform or participate in an
				  exposure-prone procedure with respect to a patient when each of the following
				  four conditions is met.
1. The practitioner
				  has affirmatively advised the patient, or the patient's lawfully authorized
				  representative, that the practitioner has been diagnosed as HBsAg seropositive
				  and/or HIV seropositive, as the case may be.
2. The patient, or the patient's lawfully
				  authorized representative, has been advised of the risk of the practitioner's
				  transmission of HBV and/or HIV to the patient during an exposure-prone
				  procedure. The practitioner, if a physician or podiatrist, shall personally
				  communicate such information to the patient or patient's representative. If the
				  practitioner is other than a physician or podiatrist, such information shall
				  also be communicated to the patient's physician.
3. The patient, or the patient's lawfully
				  authorized representative, has subscribed a written instrument setting forth:
a. identification of the exposure-prone
				  procedure to be performed by the practitioner with respect to the
				  patient;
b. an acknowledgment that
				  the advice required by §6709. A.1 have been given to and understood by
				  the patient or the patient's representative; and
c. the consent of the patient, or the
				  patient's lawfully authorized representative to the performance of or
				  participation in the designated procedure by the practitioner.
4. The practitioner's HBsAg and/or
				  HIV seropositivity has been affirmatively disclosed to each practitioner or
				  other health care personnel who participates or assists in the exposure-prone
				  procedure.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 67 - Preventing Transmission of Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) during Exposure-Prone Invasive Procedures › Section XLV-6711 - Self-Reporting

Current through Register Vol. 50, No. 6, June 20, 2024
A. Applicability.
				  Any practitioner who in the course of practice may at any time undertake to
				  perform or participate in an exposure-prone procedure and who is or becomes
				  HBsAg seropositive or HIV seropositive shall give notice of such seropositivity
				  to the board in accordance with the provisions of this Section.
B. Procedure. On or before the applicable
				  initial request deadline specified by §6711 C, a practitioner required by
				  §6711. A to report his or her HBsAg or HIV seropositivity to the board shall
				  request a self-reporting form from the board's physician medical consultant, by
				  mail directed to the confidential attention of the medical consultant or by
				  personal telephone communication with the medical consultant at the board's
				  offices. In making such request, a requesting practitioner shall advise the
				  medical consultant of the address to which the self-reporting form should be
				  mailed or delivered. Upon receipt of any such request, the medical consultant
				  will promptly mail or deliver a board-approved self-reporting form to the
				  requesting practitioner, accompanied by an addressed, postage-prepaid envelope
				  directed to the confidential attention of the medical consultant. Within 10
				  days of receipt of such form the requesting practitioner shall complete,
				  subscribe, and cause such self-reporting form to be delivered or mailed to the
				  medical consultant.
C. Initial
				  Request Deadlines. The initial request deadline for a practitioner:
1. who is HBsAg or HIV seropositive on or
				  prior to the effective date of this Chapter, or who becomes HBsAg or HIV
				  seropositive within 60 days from the effective date of this Chapter, shall be
				  90 days from the effective date of this Chapter;
2. who becomes HBsAg or HIV seropositive more
				  than 60 days from the effective date of this Chapter shall be 30 days from the
				  date on which the practitioner becomes seropositive; and
3. who is HBsAg or HIV seropositive on the
				  date on which any license, permit, or certification is issued by the board to
				  the practitioner shall be 10 days from such date.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 67 - Preventing Transmission of Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) during Exposure-Prone Invasive Procedures › Section XLV-6713 - Confidentiality of Reported Information

Current through Register Vol. 50, No. 6, June 20, 2024
A. General Confidentiality. Reports and
				  information furnished to the board pursuant to
				  §6711 of this Chapter and records of the
				  board relative to such information shall not be deemed to constitute public
				  records, but shall be deemed and maintained by the board as confidential and
				  privileged and shall not be subject to disclosure by means of subpoena in any
				  judicial, administrative, or investigative proceeding; providing that such
				  reports, information, and records may be disclosed by the board as necessary
				  for the board to investigate or prosecute alleged violations of this
				  Chapter.
B. Confidentiality of
				  Identity of Seropositive Practitioners. The identity of practitioners who have
				  reported their status as carriers of HBV or HIV to the board's medical
				  consultant pursuant to
				  §6711 hereof shall be maintained in
				  confidence by the medical consultants and shall not be disclosed to any member,
				  employee, agent, attorney, or representative of the board nor to any other
				  person, firm, organization, or entity, governmental or private, except as may
				  be necessary in the investigation or prosecution of suspected violations of
				  this Chapter.
C. Disclosure of
				  Statistical Data. Provided that the identity or self-reporting practitioners is
				  not disclosed, either directly or indirectly, the provisions of this Section
				  shall not be deemed to prevent disclosure by the medical consultant or the
				  board, to governmental public health agencies with a legitimate need therefor,
				  of statistical data derived from such reports, including, without limitation,
				  the number and licensure class of practitioners having reported themselves as
				  HBsAg and/or HIV seropositive and their geographical distribution.
AUTHORITY NOTE:
					 Promulgated in accordance with R.S. 37:1746-1747 and
					 37:1270(B)(6).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 67 - Preventing Transmission of Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) during Exposure-Prone Invasive Procedures › Section XLV-6715 - Interpretation

Current through Register Vol. 50, No. 6, June 20, 2024
A. Nothing in this
				  Chapter shall be construed to require the mandatory testing of any practitioner
				  for HBsAg or HIV seropositivity.
AUTHORITY NOTE:
					 Promulgated in accordance with R.S. 37:1746-1747 and
					 37:1270(B)(6).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 69 - Prescription, Dispensation, and Administration of Medications › Subchapter A - Medications Used in the Treatment of Obesity › Section XLV-6901 - Scope of Subchapter

Current through Register Vol. 50, No. 6, June 20, 2024
A. The
					 rules of this Subchapter govern physician prescription, dispensation,
					 administration, or other use of medications for weight control or weight
					 reduction in the medical treatment of obesity.
AUTHORITY NOTE:
						Promulgated in accordance with
						R.S.
						37:1270(A)(1),
						37:1270(B)(6),
						and
						37:1285(B).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 69 - Prescription, Dispensation, and Administration of Medications › Subchapter A - Medications Used in the Treatment of Obesity › Section XLV-6903 - Definitions

Current through Register Vol. 50, No. 6, June 20, 2024
A. As used in this
					 Subchapter, the following terms shall have the meanings specified.
Anorectic
- a drug, medication, or
						substance used or intended for use as an appetite suppressant.
Schedule II Controlled Substance
- any
						substance so classified under and pursuant to regulations of the Drug
						Enforcement Administration (DEA), U.S. Department of Justice,  21 CFR §1308 . 12,
						or any substance which may hereafter be so classified by amendment or
						supplementation of such regulation.
Schedule III Anorectic
- benzphetamine,
						phendimetrazine, and any other substance now or hereafter classified as a
						Schedule III controlled substance under and pursuant to Federal DEA
						regulations,  21 CFR §1308 . 13, and which is indicated for use in the treatment
						of exogenous obesity by express approval of the U.S. Food and Drug
						Administration (FDA).
Schedule IV Anorectic
- fenfluramine,
						dexfenfluramine, phentermine, diethylpropion, mazindol, and any other substance
						now or hereafter classified as a Schedule IV controlled substance under and
						pursuant to federal DEA regulations,  21 CFR §
												1308.14  and which is indicated for
						use in the treatment of exogenous obesity by express approval of the
						FDA.
AUTHORITY NOTE:
						Promulgated in accordance with
						R.S.
						37:1270(A)(1),
						37:1270(B)(6),
						and
						37:1285(B).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 69 - Prescription, Dispensation, and Administration of Medications › Subchapter A - Medications Used in the Treatment of Obesity › Section XLV-6905 - Prohibitions

Current through Register Vol. 50, No. 6, June 20, 2024
A. Absolute
					 Prohibitions. A physician shall not prescribe, dispense, administer, supply,
					 sell, give, or otherwise use to or for any person for the purpose of weight
					 control or weight reduction in the treatment of obesity any amphetamine,
					 dextroamphetamine, methamphetamine, or phenmetrazine drug or compound; any
					 Schedule II controlled substance; human chorionic gonadotropin (HCG); thyroid
					 hormones; diuretic medications; or any drug, medication, compound, or substance
					 which is not indicated for use in the treatment of exogenous obesity by express
					 approval of the U.S. Food and Drug Administration (FDA).
B. Schedule III-IV Anorectics. A physician
					 shall not prescribe, dispense, or administer Schedule III or Schedule IV
					 anorectics for the purpose of weight reduction or control in the treatment of
					 obesity other than in strict conformity with each of the conditions and
					 limitations prescribed by
					 §6907 of this Subchapter.
C. When a non-controlled drug has been
					 approved in the treatment of exogenous obesity by the FDA, the prohibitions in
					 Subsection A of this Section shall not prevent the individual components of
					 such drug from being separately prescribed, dispensed or administered for the
					 treatment of obesity.
AUTHORITY NOTE:
						Promulgated in accordance with
						R.S.
						37:1270(A)(1),
						37:1270(B)(6),
						and
						37:1285(B).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 69 - Prescription, Dispensation, and Administration of Medications › Subchapter A - Medications Used in the Treatment of Obesity › Section XLV-6907 - Use of Schedule III-IV Anorectics; Conditions; Limitations

Current through Register Vol. 50, No. 6, June 20, 2024
A. General
					 Conditions. A physician shall not prescribe, dispense, or administer a Schedule
					 III or Schedule IV anorectic for the purpose of weight reduction or control in
					 the treatment of obesity, except as an adjunct to a therapeutic regimen of
					 weight reduction based on prescribed sound nutrition, caloric restriction,
					 exercise, and behavior modification and otherwise in accordance with the
					 FDA-approved indications for the medication and contraindications for
					 unapproved combinations of anorectic agents. Schedule III-IV anorectics may be
					 prescribed, dispensed, or administered only to an adult patient who is obese
					 under recognized generally accepted criteria for determining obesity, whose
					 obesity is exogenous and not primarily metabolic, who is not pregnant, who does
					 not suffer from or have any disease or condition constituting a recognized
					 contraindication for use of the substance, and who otherwise satisfies the
					 conditions requisite to treatment with anorectics as prescribed by this
					 Section.
B. Requisite Prior
					 Conditions. Before initiating treatment utilizing a Schedule III or IV
					 anorectic with respect to any patient, a physician shall:
1. obtain a thorough prior history, including
					 the patient's weight loss/gain history and prior efforts at weight
					 reduction;
2. perform a thorough
					 and complete physical examination;
3. determine that the patient is a proper
					 candidate for weight reduction treatment and that the patient's obesity is not
					 primarily metabolic;
4. rule out
					 the presence of conditions recognized as contraindicating the use of anorectic
					 medications, including, without limitation, pregnancy, hypertension, and
					 hypersensitivity or idiosyncrasy to anorectics;
5. determine whether the patient has a
					 history of or any tendency or propensity toward abuse of drugs, including
					 alcohol;
6. determine that the
					 patient has made a substantial good-faith effort at weight reduction under a
					 bona fide program not utilizing anorectics;
7. take reasonable measures to ensure that
					 the patient has not previously, in the course of treatment by one or more other
					 practitioners, or otherwise, obtained and used anorectics in excess of the
					 quantitative and durational limitations on the use of anorectics prescribed by
					 §6907 E; and
8. provide the
					 patient with a carefully prescribed diet, together with counseling on exercise
					 and, as appropriate, other supportive or behavioral therapy.
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 69 - Prescription, Dispensation, and Administration of Medications › Subchapter A - Medications Used in the Treatment of Obesity › Section XLV-6909 - Exemption of Controlled Scientific Studies

Current through Register Vol. 50, No. 6, June 20, 2024
A. The prohibitions, conditions, and
					 limitations on the use of Schedule III and Schedule IV anorectic medications
					 prescribed by §6905. B and
					 §6907 of this Subchapter shall not be
					 applicable to a physician engaged in the conduct of a controlled scientific
					 study of the efficacy of such medications in the medical treatment of obesity,
					 provided that the physician is employed by or otherwise officially affiliated
					 with an accredited medical school or college or other institution of higher
					 learning located in the state of Louisiana, such study is conducted under the
					 auspices of such school, college, or institution, and the interim and final
					 results of such study are furnished to the board in writing.
AUTHORITY NOTE:
						Promulgated in accordance with
						R.S.
						37:1270(A)(1),
						37:1270(B)(6),
						and
						37:1285(B).
Louisiana Administrative Code › Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS › Part XLV - Medical Professions › Subpart 3 - Practice › Chapter 69 - Prescription, Dispensation, and Administration of Medications › Subchapter A - Medications Used in the Treatment of Obesity › Section XLV-6911 - Exceptions in Individual Cases

Current through Register Vol. 50, No. 6, June 20, 2024
A.
					 Availability of Exceptions. Upon written application to the board made in
					 accordance with this Subsection, the board may authorize a physician, with
					 respect to an identified individual patient, to exceed or otherwise depart from
					 the prohibitions, conditions, and limitations on the use of Schedule III or
					 Schedule IV anorectics otherwise prescribed by §6905. B and
					 §6907 of this Subchapter.
B. Form, Content of Application for
					 Exception. An application for board approval of an individual exception from
					 the provisions of this Subchapter shall be submitted to the board's medical
					 consultant in writing and shall contain:
1.
					 individual identification of the patient to whom the physician proposes to
					 prescribe, dispense, or administer anorectics other than in accordance with the
					 provisions of this Subchapter;
2. a
					 summary of the patient's medical and weight loss/gain history;
3. a complete copy of the patient's medical
					 record, including a record of all anorectic medications prescribed, dispensed,
					 or administered to or for the patient within 24 months prior to the
					 application;
4. a statement by the
					 physician of the specific manner in which the physician proposes to deviate
					 from the provisions of this Subchapter respecting the prescription,
					 dispensation, and administration of anorectic medications, together with a
					 statement by the physician of the medical facts and circumstances deemed by the
					 physician to justify such departure; and
5. such other information and documentation
					 as the board or its medical consultant may request.